Literature DB >> 3002134

Validity of certified causes of death in breast carcinoma patients.

L E Rutqvist.   

Abstract

The accuracy of the cause of death certification was surveyed in 802 breast carcinoma patients reported to the Swedish Cancer Registry from Stockholm county during 1961-1963. A total of 502 deaths occurred during the follow-up period of which 484 were eligible for the analysis. In 7 per cent the officially recorded underlying cause of death failed to accurately reflect the cancer status at death, which was mostly due to diagnostic errors or errors in the coding of the death certificate data. There seemed to be a net overestimation of intercurrent deaths in the official mortality statistics and a corresponding net underestimation of breast carcinoma deaths. Breast carcinoma was mentioned as a contributory cause of death in only 52 per cent of those certified to have died from intercurrent causes but who had recurrent disease at death. Among those with breast carcinoma as a certified contributory cause, 52 per cent did not have recurrent disease according to the clinical records. It is therefore concluded that official data on breast carcinoma as a contributory cause of death are of limited use in descriptive epidemiology.

Entities:  

Mesh:

Year:  1985        PMID: 3002134     DOI: 10.3109/02841868509134405

Source DB:  PubMed          Journal:  Acta Radiol Oncol        ISSN: 0349-652X


  7 in total

1.  Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study.

Authors:  Shaheenah Dawood; Rong Hu; Michelle D Homes; Laura C Collins; Stuart J Schnitt; James Connolly; Graham A Colditz; Rulla M Tamimi
Journal:  Breast Cancer Res Treat       Date:  2010-08-14       Impact factor: 4.872

2.  Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer.

Authors:  Tomasz P Srokowski; Shenying Fang; Gabriel N Hortobagyi; Sharon H Giordano
Journal:  J Clin Oncol       Date:  2009-03-23       Impact factor: 44.544

3.  Risk of hospitalisation and death due to bone fractures after breast cancer: a registry-based cohort study.

Authors:  Edoardo Colzani; Mark Clements; Anna L V Johansson; Annelie Liljegren; Wei He; Judith Brand; Jan Adolfsson; Tommy Fornander; Per Hall; Kamila Czene
Journal:  Br J Cancer       Date:  2016-10-04       Impact factor: 7.640

4.  Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.

Authors:  Laura J van 't Veer; Christina Yau; Nancy Y Yu; Christopher C Benz; Bo Nordenskjöld; Tommy Fornander; Olle Stål; Laura J Esserman; Linda Sofie Lindström
Journal:  Breast Cancer Res Treat       Date:  2017-08-04       Impact factor: 4.872

5.  Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer.

Authors:  Linda S Lindström; Christina Yau; Kamila Czene; Carlie K Thompson; Katherine A Hoadley; Laura J Van't Veer; Ron Balassanian; John W Bishop; Philip M Carpenter; Yunn-Yi Chen; Brian Datnow; Farnaz Hasteh; Gregor Krings; Fritz Lin; Yanhong Zhang; Bo Nordenskjöld; Olle Stål; Christopher C Benz; Tommy Fornander; Alexander D Borowsky; Laura J Esserman
Journal:  J Natl Cancer Inst       Date:  2018-07-01       Impact factor: 13.506

6.  Is genetic background important in lung cancer survival?

Authors:  Linda S Lindström; Per Hall; Mikael Hartman; Fredrik Wiklund; Kamila Czene
Journal:  PLoS One       Date:  2009-05-29       Impact factor: 3.240

7.  Time-dependent risk of developing distant metastasis in breast cancer patients according to treatment, age and tumour characteristics.

Authors:  E Colzani; A L V Johansson; A Liljegren; T Foukakis; M Clements; J Adolfsson; P Hall; K Czene
Journal:  Br J Cancer       Date:  2014-01-16       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.